证券代码： 600566 证券简称： 济川药业 公告编号： 2025-082 湖北济川药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1 二、药物其他情况 利多卡因是一种酰胺类局部麻醉剂，通过抑制神经冲动发生与传导所需的离 子通道而起到稳定神经细胞膜作用。利多卡因凝胶贴膏最早于 1999 年 3 月在美 国上市，持证商为 Teikoku Pharma USA, Inc，商品名为 Lidoderm ®，上市剂型为 贴膏剂，适应症为用于缓解带状疱疹后遗神经痛。 陕西东科的利多卡因凝胶贴膏注册分类为化学药品 3 类，按照与参比制剂质 量和疗效一致的技术要求审评并获批，批准后视同通过仿制药质量和疗效一致性 评价，用于缓解带状疱疹后神经痛，用于无破损皮肤。 截至目前，除原研进口外，国内已有 4 家企业（含陕西东科）获批利多卡因 凝胶贴膏。据米内网数据显示，2024 年中国城市公立医院利多卡因凝胶贴膏的 销售额为 6,475 万元。 截至本公告披露日，该药品累计研发支出约 1,749.2 ...

Core Viewpoint - Jichuan Pharmaceutical has received approval for its Lidocaine Gel Patch from the National Medical Products Administration, which may enhance its product portfolio and revenue potential [1] Company Summary - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Lidocaine Gel Patch [1] - As of the latest report, Jichuan Pharmaceutical's market capitalization stands at 23.5 billion yuan [1] Revenue Composition - For the year 2024, Jichuan Pharmaceutical's revenue composition is as follows: - Heat-clearing and detoxifying products: 33.53% - Pediatric products: 28.11% - Digestive products: 14.41% - Other sectors: 9.94% - Respiratory products: 8.13% [1]

Core Viewpoint - Jichuan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., has received the drug registration certificate for Lidocaine Gel Patch from the National Medical Products Administration [1] Group 1: Company Information - The company is involved in the pharmaceutical industry, specifically focusing on the development and production of local anesthetics [1] - Lidocaine is classified as an amide-type local anesthetic, which functions by stabilizing the nerve cell membrane through the inhibition of ion channels necessary for nerve impulse generation and conduction [1] Group 2: Regulatory Approval - The approval from the National Medical Products Administration signifies a regulatory milestone for the company, allowing it to market the Lidocaine Gel Patch [1]

Core Viewpoint - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke, has received approval from the National Medical Products Administration for the registration certificate of Lidocaine Gel Patch, which is intended for alleviating postherpetic neuralgia [2] Company Summary - The approval of the Lidocaine Gel Patch is seen as a significant addition to the company's product line, which is expected to positively impact its future development [2] - Currently, there are four companies in China, including Shaanxi Dongke, that have been approved for the Lidocaine Gel Patch [2] Industry Summary - The market development cycle for the newly approved drug may be lengthy and is subject to uncertainties influenced by industry policies and procurement bidding [2]

Core Viewpoint - Jichuan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., received the drug registration certificate for Lidocaine Gel Patch from the National Medical Products Administration [1] Group 1: Company Information - The drug registration certificate pertains to Lidocaine, an amide local anesthetic that stabilizes nerve cell membranes by inhibiting the ion channels required for nerve impulse generation and conduction [1]

Core Viewpoint - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke Pharmaceutical, has received approval from the National Medical Products Administration for the registration certificate of Lidocaine Gel Patch, indicating a significant advancement in the company's product portfolio [1] Company Summary - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke, is now authorized to market Lidocaine, an amide-type local anesthetic, which works by stabilizing nerve cell membranes through the inhibition of ion channels necessary for nerve impulse conduction [1]

Core Viewpoint - Hubei Jichuan Pharmaceutical Co., Ltd. announced that its controlling shareholder, Jiangsu Jichuan Holding Group Co., Ltd., has released the pledge on 43 million shares, resulting in no pledged shares remaining [2]. Group 1 - The controlling shareholder, Jiangsu Jichuan Holding Group, holds 416,757,360 shares, accounting for 45.27% of the total share capital of the company [2]. - After the release of the pledge, Jiangsu Jichuan Holding has no further plans for share pledges and will fulfill disclosure obligations if any new pledges occur [2].

证券日报网讯 9月15日晚间，济川药业发布公告称，控股股东江苏济川控股集团有限公司（简称"济川 控股"）持有公司无限售流通股份416，757，360股，占公司总股本45.27%。本次济川控股解除质押股 份的数量为43，000，000股，占其所持股份比例10.32%，占公司总股本比例4.67%。本次解除质押后， 济川控股持有的公司股份已不存在被质押的情形。 （文章来源：证券日报） ...

Core Viewpoint - Jichuan Pharmaceutical announced the release of 43 million shares from pledge by its controlling shareholder, Jiangsu Jichuan Holding Group, which holds approximately 417 million shares, accounting for 45.27% of the total share capital [1] Company Summary - Jichuan Pharmaceutical's revenue composition for the year 2024 is as follows: 33.53% from heat-clearing and detoxifying products, 28.11% from pediatric products, 14.41% from digestive products, 9.94% from other industries, and 8.13% from respiratory products [1] - As of the report date, Jichuan Pharmaceutical has a market capitalization of 23.6 billion yuan [1]

关于控股股东股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 股东名称 | 江苏济川控股集团有限公司 | | --- | --- | | 本次解除质押股份（股） | 43,000,000 | | 占其所持股份比例 | 10.32% | | 占公司总股本比例 | 4.67% | | 解除质押时间 | 2025 年 9 月 12 日 | | 持股数量 | 416,757,360 | | 持股比例 | 45.27% | | 剩余被质押股份数量（股） | 0 | | 剩余被质押股份数量占其所持股份比例 | 0% | | 剩余被质押股份数量占公司总股本比例 | 0% | 本次解除质押股份后，济川控股暂无后续质押计划，若再发生质押事项，后 续将根据实际质押情况及时履行告知义务,公司将按照相关法律法规要求及时履 行信息披露义务。 特此公告。 湖北济川药业股份有限公司 证券代码： 600566 证券简称： 济川药业 公告编号： 2025-081 重要内容提示： 公司于近日获悉控股股东济川控股所持有本公司的股份解除质押，具 ...